Info
Experienced scientific and people leader with a demonstrated history of working in the biotechnology industry. Enthusiastic research professional skilled in Antibodies, Immunology, Biotechnology, Drug Discovery & Development. Loves to make connections, eager to discover and create. Passionate about science and art. Aims to drive research & innovation to unexplored areas.
Artikelen van Janine
-
Join us: GRC Antibody Biology & Engineering
Join us: GRC Antibody Biology & Engineering
Van Janine Schuurman
-
Write down your ideas - deadline approaching ....
Write down your ideas - deadline approaching ....
Van Janine Schuurman
Activiteit
-
Very grateful for the BiotechBuilders Award. Thanks to all students, team members and collaborators who have equal part in this recognition…
Very grateful for the BiotechBuilders Award. Thanks to all students, team members and collaborators who have equal part in this recognition…
Gemarkeerd als interessant door Janine Schuurman
-
🎉 Celebrating 3 years of Commit Biologics! 🎉 On September 1st, 2021, our co-founders Nick Stub Laursen, Dennis Pedersen, Mikael B. L. Winkler…
🎉 Celebrating 3 years of Commit Biologics! 🎉 On September 1st, 2021, our co-founders Nick Stub Laursen, Dennis Pedersen, Mikael B. L. Winkler…
Gemarkeerd als interessant door Janine Schuurman
-
At Commit Biologics we are harnessing the power of the complement system, a vital part of our immune system, to treat cancer and autoimmune disease.…
At Commit Biologics we are harnessing the power of the complement system, a vital part of our immune system, to treat cancer and autoimmune disease.…
Gemarkeerd als interessant door Janine Schuurman
Ervaring
Opleiding
Publicaties
-
Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
Molecular Immunology
Complement-dependent cytotoxicity is an important mechanism of action of certain mAbs used in cancer immunotherapy, including ofatumumab and rituximab. However, the detailed sequence of cellular changes that occur in nucleated cells attacked by mAb and complement has not been delineated. Recently developed CD20 mAbs, engineered to form hexamers on binding to cells, react with B-cells in serum, chelate C1q, and then activate complement and promote cell killing considerably more effectively than…
Complement-dependent cytotoxicity is an important mechanism of action of certain mAbs used in cancer immunotherapy, including ofatumumab and rituximab. However, the detailed sequence of cellular changes that occur in nucleated cells attacked by mAb and complement has not been delineated. Recently developed CD20 mAbs, engineered to form hexamers on binding to cells, react with B-cells in serum, chelate C1q, and then activate complement and promote cell killing considerably more effectively than their wild-type precursors. We used these engineered mAbs as a model to investigate the sequence of events that occur when mAbs bind to B-cell lines and to primary cells from patients with chronic lymphocytic leukemia and then activate complement. Based on four-color confocal microscopy real-time movies and high resolution digital imaging, we find that after CD20 mAb binding and C1q uptake, C3b deposits on cells, followed by Ca2+ influx, revealed by bright green signals generated on cells labeled with FLUO-4, a Ca2+ indicator. The bright FLUO-4/Ca2+ signal fades, replaced by punctate green signals in mitochondria, indicating Ca2+ localization. This step leads to mitochondrial poisoning followed by cell death. The entire sequence is completed in <2 min for hexamerization-enhanced CD20 mAb-mediated killing. To our knowledge this is the first time the entire process has been characterized in detail in real time. By identifying multiple discrete steps in the cytotoxic pathway for nucleated cells our findings may inform future development and more effective application of complement-fixing mAbs to cancer treatment.
Andere auteursPublicatie weergeven -
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
PLOS Biology
IgG antibodies can organize into ordered hexamers on cell surfaces after binding their antigen. These hexamers bind the first component of complement C1 inducing complement-dependent target cell killing. Here, we translated this natural concept into a novel technology platform (HexaBody technology) for therapeutic antibody potentiation. We identified mutations that enhanced hexamer formation and complement activation by IgG1 antibodies against a range of targets on cells from hematological and…
IgG antibodies can organize into ordered hexamers on cell surfaces after binding their antigen. These hexamers bind the first component of complement C1 inducing complement-dependent target cell killing. Here, we translated this natural concept into a novel technology platform (HexaBody technology) for therapeutic antibody potentiation. We identified mutations that enhanced hexamer formation and complement activation by IgG1 antibodies against a range of targets on cells from hematological and solid tumor indications. IgG1 backbones with preferred mutations E345K or E430G conveyed a strong ability to induce conditional complement-dependent cytotoxicity (CDC) of cell lines and chronic lymphocytic leukemia (CLL) patient tumor cells, while retaining regular pharmacokinetics and biopharmaceutical developability. Both mutations potently enhanced CDC- and antibody-dependent cellular cytotoxicity (ADCC) of a type II CD20 antibody that was ineffective in complement activation, while retaining its ability to induce apoptosis. The identified IgG1 Fc backbones provide a novel platform for the generation of therapeutics with enhanced effector functions that only become activated upon binding to target cell–expressed antigen.
Andere auteursPublicatie weergeven
Ontvangen aanbevelingen
1 persoon heeft Janine aanbevolen
Word nu lid om dit te bekijkenMeer activiteiten van Janine
-
Thanks, FairJourney Biologics! We'll be there. For our followers who first want to catch up on talks from 2023 that they missed, we have a list of…
Thanks, FairJourney Biologics! We'll be there. For our followers who first want to catch up on talks from 2023 that they missed, we have a list of…
Gemarkeerd als interessant door Janine Schuurman
-
📣FANTASTIC NEWS📣 Yesterday the BiotechBuilders Award 2024 was announced. 🎺🎺🎺🎺 Congratulations 🥳to our co-founder Johan Rockberg for this…
📣FANTASTIC NEWS📣 Yesterday the BiotechBuilders Award 2024 was announced. 🎺🎺🎺🎺 Congratulations 🥳to our co-founder Johan Rockberg for this…
Gemarkeerd als interessant door Janine Schuurman
-
Amazing to see our people working up until the very end. This is an incredible display of commitment to science and to patients. If there was EVER…
Amazing to see our people working up until the very end. This is an incredible display of commitment to science and to patients. If there was EVER…
Gemarkeerd als interessant door Janine Schuurman
-
Latest publication evaluating #CrossMab bispecifics amongst other bsAb formats for NKp46-based NK cell engagers by Robert Lee, Jennifer Cochran and…
Latest publication evaluating #CrossMab bispecifics amongst other bsAb formats for NKp46-based NK cell engagers by Robert Lee, Jennifer Cochran and…
Gemarkeerd als interessant door Janine Schuurman
-
Dat is even wat anders om een bruiloft te fotograferen. Het was een mooie ceremonie wat heel veel mooie, leuke en ook emotionele beelden opleverde…
Dat is even wat anders om een bruiloft te fotograferen. Het was een mooie ceremonie wat heel veel mooie, leuke en ook emotionele beelden opleverde…
Gemarkeerd als interessant door Janine Schuurman
-
https://lnkd.in/e5tJwSJG
https://lnkd.in/e5tJwSJG
Gemarkeerd als interessant door Janine Schuurman
-
It's been a busy and exciting summer for Diagonal! We recently moved out of an incubator space and into our very own office in Arsenal Yards…
It's been a busy and exciting summer for Diagonal! We recently moved out of an incubator space and into our very own office in Arsenal Yards…
Gemarkeerd als interessant door Janine Schuurman
-
Enlightening discussion with Peyton Greenside from BigHat Biosciences on the role of AI and Machine learning in Antibody Discovery and Engineering…
Enlightening discussion with Peyton Greenside from BigHat Biosciences on the role of AI and Machine learning in Antibody Discovery and Engineering…
Gemarkeerd als interessant door Janine Schuurman
-
Thanks to BioCentury Inc.’s Danielle Golovin, Ph.D. for featuring us in this emerging company profile. Danielle and our CEO Alexey "Alex" Lugovskoy…
Thanks to BioCentury Inc.’s Danielle Golovin, Ph.D. for featuring us in this emerging company profile. Danielle and our CEO Alexey "Alex" Lugovskoy…
Gemarkeerd als interessant door Janine Schuurman
Overige vergelijkbare profielen
Anderen hebben Janine Schuurman genoemd
2 anderen door wie Janine Schuurman is genoemd, gebruiken LinkedIn
Bekijk anderen die Janine Schuurman heten